Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224 · View on ClinicalTrials.gov ↗
Study Summary
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)
Conditions Studied
Interventions
- DRUG APL-101 Oral Capsules
Study Locations (20)
Other
- St Vincents Hospital Melbourne — Melbourne
- Cross Cancer Institute — Edmonton
- McGill University Health Center - Research Institute — Montreal
- Princess Margaret Hospital — Toronto
- Cancer Care Manitoba — Winnipeg
- CHRU de Brest - Hôpital Morvan — Brest
- Centre Leon Berard — Lyon
- Centre d'Essais Precoces en Cancerologie de Marseille — Marseille
- Hopital Bichat - Claude Bernard - AP-HP — Paris
- Gustave Roussy — Villejuif
- Orszagos Koranyi Pulmonologiai Intezet — Budapest
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz — Tatabánya
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola — Bologna
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori — Meldola
California
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute — Los Angeles
Florida
- Moffitt — Tampa
Massachusetts
- Dana Farber Cancer Institute — Boston
North Carolina
- University of North Carolina — Chapel Hill
Pennsylvania
- Penn State Milton S. Hershey Medical Center — Hershey
Wisconsin
- University of Wisconsin — Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 497 participants |
| Start Date | 2017-09-27 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03175224
The ClinicalTrials.gov registry entry for NCT03175224 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 497 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apollomics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention — of which APL-101 Oral Capsules is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03175224 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Other, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03175224 about?
NCT03175224 is a clinical study titled "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors". To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w...
What is the current status of trial NCT03175224?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 497 participants. The study started on 2017-09-27. Estimated completion is 2026-11-30.
What conditions does trial NCT03175224 study?
This clinical trial studies the following conditions: Lung Cancer, Gastric Cancer, Solid Tumors, Advanced Cancer, Glioblastoma Multiforme. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03175224?
The interventions under investigation include: APL-101 Oral Capsules (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03175224?
This trial is sponsored by Apollomics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03175224 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.